SCHEMBL5404093

SCHEMBL5404093

CN(C(=O)c1ccccc1-c1ccccc1C(=O)N(CCC(=O)O)CCc1ccccn1)c1cccs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.40
HCRTR2 O43614 3/20 0.40
RAF1 P04049 1/20 0.39
MAP2K1 Q02750 1/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 4/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
HIF1A Q16665 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
F2 P00734 1/20 0.36
F10 P00742 1/20 0.36
F7 P08709 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407120 0.86 KMT2A (0.41) NPC1POLBRAB9ACYP1A2CYP3A4
SCHEMBL5409193 0.85 TSHR (0.43) LMNANPC1POLBALDH1A1TSHR
SCHEMBL5402834 0.85 HCRTR1 (0.43) HCRTR1HCRTR2RAF1MAP2K1LMNA
SCHEMBL5402237 0.83 TBXAS1 (0.42) HTT
SCHEMBL5404063 0.83 KDM4A (0.40) NPC1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL5399037 0.83 TRPM8 (0.39) CYP3A4SMN1; SMN2ALDH1A1
SCHEMBL5399258 0.83 POLB (0.36) HCRTR1HCRTR2LMNAHTTPOLB
SCHEMBL5404096 0.81 LMNA (0.50) LMNAHTTKDM4EPOLBCYP1A2
SCHEMBL5397881 0.81 TRPV1 (0.41) HCRTR1HCRTR2RAF1MAP2K1LMNA
SCHEMBL5399135 0.81 CYP2D6 (0.43) LMNAKDM4ENPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB HCRTR1 2878/4885HCRTR2 2515/4885RAF1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.